Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A cost-effectiveness analysis

Journal of Thrombosis and Haemostasis

Volumn 11, Issue 1, 2013, Pages 81-91

  Lala, A ^a   Berger, J S ^a   Sharma, G ^a   Hochman, J S ^a   Scott Braithwaite, R ^a   Ladapo, J A ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute coronary syndromes; Antiplatelet therapy; Clopidogrel; Cost effectiveness; Genetic testing; Prasugrel

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; PRASUGREL;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG FATALITY; GENETIC ANALYSIS; GENOTYPE; HEALTH CARE COST; HEART INFARCTION; HUMAN; MEDICARE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; RISK FACTOR; WILD TYPE;

ACUTE CORONARY SYNDROME; ARYL HYDROCARBON HYDROXYLASES; CEREBROVASCULAR DISORDERS; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DISEASE-FREE SURVIVAL; DRUG COSTS; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HEALTH CARE COSTS; HEMORRHAGE; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; KAPLAN-MEIER ESTIMATE; MARKOV CHAINS; MEDICARE; MODELS, ECONOMIC; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PHARMACOGENETICS; PHENOTYPE; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PREDICTIVE VALUE OF TESTS; QUALITY-ADJUSTED LIFE YEARS; RISK ASSESSMENT; RISK FACTORS; THIOPHENES; THROMBOSIS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84873033234     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12059     Document Type: Article

References (44)

1. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
2. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, McCabe CH, Braunwald E. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179-89.
3. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, Liu LS. Addition of clopidogrel to aspirin in 45, 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366: 1607-21.
4. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-15.
5. Ancrenaz V, Daali Y, Fontana P, Besson M, Samer C, Dayer P, Desmeules J. Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability. Curr Drug Metab 2010; 11: 667-77.
6. Gurbel PA, Tantry US, Shuldiner AR. The worry about clopidogrel "nonresponsiveness": identification and treatment in the post-percutaneous coronary intervention patient. JACC Cardiovasc Interv 2009; 2: 1102-4.
7. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod H. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-5.
8. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-62.
9. Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, Simon T, Antman EM, Braunwald E, Sabatine MS. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 2010; 376: 1312-9.
10. Varenhorst C, James S, Erlinge D, Brandt JT, Braun OO, Man M, Siegbahn A, Walker J, Wallentin L, Winters KJ, Close SL. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur Heart J 2009; 30: 1744-52.
11. Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot JS, Kastrati A, Montalescot G, Neumann FJ, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 2010; 304: 1821-30.
12. Antoniades C, van-Assche T, Shirodaria C, Diesch J, Antonopoulos AS, Lee J, Cunnington C, Tousoulis D, Stefanadis C, Casadei B, Taggart D, Channon KM, Leeson P. Preoperative sCD40L levels predict risk of atrial fibrillation after off-pump coronary artery bypass graft surgery. Circulation 2009; 120: S170-6.
13. Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM. ACCF/AHA Clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation 2010; 122: 537-57.
14. Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS. What does the value of modern medicine say about the $50, 000 per quality-adjusted life-year decision rule? Med Care 2008; 46: 349-56.
15. Daly TM, Dumaual CM, Miao X, Farmen MW, Njau RK, Fu DJ, Bauer NL, Close S, Watanabe N, Bruckner C, Hardenbol P, Hockett RD. Multiplex assay for comprehensive genotyping of genes involved in drug metabolism, excretion, and transport. Clin Chem 2007; 53: 1222-30.
16. Dumaual C, Miao X, Daly TM, Bruckner C, Njau R, Fu DJ, Close-Kirkwood S, Bauer N, Watanabe N, Hardenbol P, Hockett RD. Comprehensive assessment of metabolic enzyme and transporter genes using the Affymetrix Targeted Genotyping System. Pharmacogenomics 2007; 8: 293-305.
17. Brilakis ES, Hernandez AF, Dai D, Peterson ED, Banerjee S, Fonarow GC, Cannon CP, Bhatt DL. Quality of care for acute coronary syndrome patients with known atherosclerotic disease: results from the Get With the Guidelines Program. Circulation 2009; 120: 560-7.
18. Abtahian F, Olenchock B, Ou FS, Kontos MC, Saucedo JF, Scirica BM, Desai N, Peterson E, Roe M, Cannon CP, Wiviott SD. Effect of prior stroke on the use of evidence-based therapies and in-hospital outcomes in patients with myocardial infarction (from the NCDR ACTION GWTG registry). Am J Cardiol 2011; 107: 1441-6.
19. Berger JS, Bhatt DL, Steg PG, Steinhubl SR, Montalescot G, Shao M, Hacke W, Fox KA, Berger PB, Topol EJ, Lincoff AM. Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J 2011; 162: 98-105.
20. Udelson JE, Pearte CA, Kimmelstiel CD, Kruk M, Kufera JA, Forman SA, Teresinska A, Bychowiec B, Marin-Neto JA, Hochtl T, Cohen EA, Caramori P, Busz-Papiez B, Adlbrecht C, Sadowski ZP, Ruzyllo W, Kinan DJ, Lamas GA, Hochman JS. The Occluded Artery Trial (OAT) Viability Ancillary Study (OAT-NUC): influence of infarct zone viability on left ventricular remodeling after percutaneous coronary intervention versus optimal medical therapy alone. Am Heart J 2011; 161: 611-21.
21. Gluckman TJ, McLean RC, Schulman SP, Kickler TS, Shapiro EP, Conte JV, McNicholas KW, Segal JB, Rade JJ. Effects of aspirin responsiveness and platelet reactivity on early vein graft thrombosis after coronary artery bypass graft surgery. J Am Coll Cardiol 2011; 57: 1069-77.
22. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias WL, Braunwald E, Sabatine MS. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009; 119: 2553-60.
23. Chaitman BR, Hardison RM, Adler D, Gebhart S, Grogan M, Ocampo S, Sopko G, Ramires JA, Schneider D, Frye RL. The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction. Circulation 2009; 120: 2529-40.
24. Sheifer SE, Gersh BJ, Yanez ND3rd, Ades PA, Burke GL, Manolio TA. Prevalence, predisposing factors, and prognosis of clinically unrecognized myocardial infarction in the elderly. J Am Coll Cardiol 2000; 35: 119-26.
25. Wiviott SD, Antman EM, Gibson CM, Montalescot G, Riesmeyer J, Weerakkody G, Winters KJ, Warmke JW, McCabe CH, Braunwald E. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J 2006; 152: 627-35.
26. Refaai M, Laposta M. Platelet Aggregaton. In: Michelson AD, ed. Platelets. San Diego, CA: Academic Press, 2002: 291-6.
27. Sullivan PW, Ghushchyan V. Preference-Based EQ-5D index scores for chronic conditions in the United States. Med Decis Making 2006; 26: 410-20.
28. Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011; 154: 1-11.
29. Mahoney EM, Wang K, Arnold SV, Proskorovsky I, Wiviott S, Antman E, Braunwald E, Cohen DJ. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Circulation 2010; 121: 71-9.
30. Thompson CA. Clopidogrel poor metabolizers may need alternative to standard regimen. Am J Health-Syst Pharm 2010; 67: 779-80.
31. Bureau of Labor & Statistics Consumer Price Index Calculator. Available at: http://www.bls.gov/data/inflation_calculator.htm. Accessed July 12, 2012.
32. Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, Horrow J, Husted S, Katus H, Steg PG, Shah SH, Becker RC. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010; 376: 1320-8.
33. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz RE. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998; 339: 1665-71.
34. Pare G, Mehta SR, Yusuf S, Anand SS, Connolly SJ, Hirsh J, Simonsen K, Bhatt DL, Fox KA, Eikelboom JW. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. New Engl J Med 2010; 363: 1704-14.
35. Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA 2011; 306: 2704-14.
36. Roberts JD, Wells GA, Le May MR, Labinaz M, Glover C, Froeschl M, Dick A, Marquis JF, O'Brien E, Goncalves S, Druce I, Stewart A, Gollob MH, So DY. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet 2012; 379: 1705-11.
37. Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, Morath T, Schomig A, von BeckerathN, Kastrati A. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 2010; 121: 512-8.
38. FDA approves Brillinta. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm263964.htm. Accessed 12 July 2012.
39. Crespin DJ, Federspiel JJ, Biddle AK, Jonas DE, Rossi JS. Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysis. Value Health 2011; 14: 483-91.
40. Centers for Medicare Medicaid Services (CMS), HHS. Medicaid program; cost limit for providers operated by units of government and provisions to ensure the integrity of federal-state financial partnership. Final rule; implementation of court orders. Fed Regist 2010; 75: 73972-6.
41. Centers for Medicare Medicaid Services (CMS), HHS. Medicare program; inpatient rehabilitation facility prospective payment system for federal fiscal year 2012; changes in size and square footage of inpatient rehabilitation units and inpatient psychiatric units. Final rule. Fed Regist. 2011; 76: 47836-915.
42. Hogan C, Lunney J, Gabel J, Lynn J. Medicare beneficiaries' costs of care in the last year of life. Health Aff (Millwood) 2001; 20: 188-95.
43. Hoover DR, Crystal S, Kumar R, Sambamoorthi U, Cantor JC. Medical expenditures during the last year of life: findings from the 1992-1996 Medicare current beneficiary survey. Health Serv Res 2002; 37: 1625-42.
44. Meara E, White C, Cutler DM. Trends in medical spending by age, 1963-2000. Health Aff (Millwood) 2004; 23: 176-83.